| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2331SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-355SS | |||
| Azide and BSA Free | NBP2-80931 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-318SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-164SS | |||
| Azide and BSA Free | NBP2-80593 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-402SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19167SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-05767SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-317SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-92156-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-36573SS | |||
| Azide and BSA Free | NBP2-80951 | |||
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - High autophagosome concentration is consumed during early immortalized human mesenchymal stem cell differentiation. Immortalized human mesenchymal stem cells were differentiated under osteogenic conditions (see Materials and methods) and assayed for changes in LC3I and LC3II during a 72-hour window. Cells were differentiated under standard conditions (top) or with addition of 5 uM rapamycin (middle) or 5 nM bafilomycin (bottom) for the first 3 hours of differentiation to modulate autophagy. Immunoblots were performed for LC3 at the indicated time points to assess autophagosome degradation via relative changes in LC3II (lower band; 17 kDa). Studies were repeated three times with similar trends seen consistently. Image collected and cropped by CiteAb from the following publication (//stemcellres.com/content/5/6/140), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Western-Blot-NB100-2331-img0041.jpg "Western Blot: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - High autophagosome concentration is consumed during early immortalized human mesenchymal stem cell differentiation. Immortalized human mesenchymal stem cells were differentiated under osteogenic conditions (see Materials and methods) and assayed for changes in LC3I and LC3II during a 72-hour window. Cells were differentiated under standard conditions (top) or with addition of 5 uM rapamycin (middle) or 5 nM bafilomycin (bottom) for the first 3 hours of differentiation to modulate autophagy. Immunoblots were performed for LC3 at the indicated time points to assess autophagosome degradation via relative changes in LC3II (lower band; 17 kDa). Studies were repeated three times with similar trends seen consistently. Image collected and cropped by CiteAb from the following publication (//stemcellres.com/content/5/6/140), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - Analysis in PFA fixed NIH/3T3 cells using anti-LC3A antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-2331-img0046.jpg)
![Immunohistochemistry: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - Staining in mouse meniscus and cartilage. Image from verified customer review.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Immunohistochemistry-NB100-2331-img0045.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - Autophagy mobilized during differentiation of immortalized human mesenchymal stem cells (ihMSCs). Cultured ihMSCs were stimulated to undergo osteogenesis to form osteoblasts for 30 days at 21% and 4% oxygen. LC3I and LC3II levels were assessed via immunoblot every 10 days and normalized to beta-actin to derive average LC3II band densities. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25523618/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LC3A Antibody - BSA Free-Western Blot-NB100-2331-img0047.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - Autophagy mobilized during differentiation of immortalized human mesenchymal stem cells (ihMSCs). Cultured ihMSCs were stimulated to undergo osteogenesis to form osteoblasts for 30 days at 21% and 4% oxygen. LC3I and LC3II levels were assessed via immunoblot every 10 days and normalized to beta-actin to derive average LC3II band densities. Image collected and cropped by CiteAb from the following publication (//stemcellres.com/content/5/6/140), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Western-Blot-NB100-2331-img0036.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - This LC3A antibody Image shows Analysis in human cell lysates.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Western-Blot-NB100-2331-img0037.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - This LC3A antibody Image shows analysis of heart tissue lysates from mice which were subjected or not to 48 hours of starvation. The signal was developed using ECL method and this LC3 antibody was found to detect both forms of LC3, i.e. LC3A and LC3B. As expected, the levels of LC3B form were higher in the heart tissue lysates from starved mice.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Western-Blot-NB100-2331-img0039.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - Detection of HRP conjugated autophagic LC3 in mouse ES cell lysate. The atg5-/- lane (ES cells, cultured to form embryonic bodies, that are deficient in conversion of LC3-1 to LC3-11) demonstrates the specificity of NB 100-2331, as there is no detection of LC3-11. Photo courtesy of Dr. Beth Levine, UT Southwestern Medical Center.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Western-Blot-NB100-2331-img0040.jpg)
![Immunocytochemistry/Immunofluorescence: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - This LC3A antibody Image shows an analysis in HeLa cells using anti-LC3 antibody (red). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-2331-img0038.jpg)
![Immunocytochemistry/Immunofluorescence: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - Left panel shows untreated HeLa cells. Right panel shows HeLa cells that were treated with 50 uM CQ overnight. Cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-LC3A antibody at 5 ug/mL overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-2331-img0042.jpg)
![Immunohistochemistry: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - Rapamycin increases autophagy in brains of PDAPP mice. Representative epifluorescent (c200x) image of hippocampal CA1 in control- and rapamycin-fed transgenic PDAPP mice stained with an anti-LC3 antibody. An increase in LC3-immunoreactive puncta was observed in CA1 projections of transgenic PDAPP mice following rapamycin administration. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0009979) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Immunohistochemistry-NB100-2331-img0043.jpg)
![Immunohistochemistry: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - Analysis in mouse renal tissue. Image from verifed customer review.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Immunohistochemistry-NB100-2331-img0044.jpg)
![Simple Western: LC3A Antibody - BSA Free [NB100-2331] - LC3A Antibody [NB100-2331] - Image shows a specific band for LC3 in 0.5 mg/mL of Neuro2A lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LC3A-Antibody---BSA-Free-Simple-Western-NB100-2331-img0025.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - Chronic, third window RIC increases the expression of autophagosome proteins, LC3I/II & Atg5.(A) Western blots for autophagy related signaling proteins. (B) Quantification of the protein fold change in 3W RIC compared to 3W controls. Values are means ± S.E.M. n = 6–8 per group. An (*) denotes a statistically significant difference (P10 larvae/sample). Lc3 c & e, or p62 & Optineurin d protein levels were detected in absence or presence of BafA1, c & d, or in the presence or absence of Mm e. Actin was used as a loading control. Western Blots were repeated three, c & d, or two e times with protein extracts derived from independent experiments. The Lc3II/Actin or p62/Actin & Optineurin/Actin ratio, normalized to the control sample, is indicated below the blots. f–g Representative confocal micrographs & quantification of GFP-Lc3 co-localization with Mm clusters in infected dram1∆19n/∆19n & dram1+/+ larvae. The top images f show the entire region of imaging, while the bottom images f′ & f″ show details of GFP-Lc3 colocalization of Mm clusters in dram1∆19n/∆19n & dram1+/+ larvae. The arrowheads indicate GFP-Lc3-positive Mm clusters. The data is accumulated from two independent experiments (≥15 larvae/group) & represented by scatter & boxplots as detailed in the “Methods” section. Scale bars, 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32332700), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2331_rabbit-polyclonal-lc3a-antibody-31020241612632.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - Optn or p62 deficiency affects autophagosome formation.(A) Workflow of the experiments shown in (B-G). Larvae were treated with 100 nM of Baf A1 for 12 h from 3.5 dpf. The GPF-Lc3 negative larvae were selected to assay autophagy activity by Western blot, the GFP-Lc3 positive larvae were collected to monitor autophagic activity using confocal imaging. The red square indicates the region for confocal imaging. (B) Level of basal autophagy in WT & mutant embryos in absence or presence of Baf A1. Protein samples were extracted from 4 dpf WT & mutant larvae (>10 embryos/sample). The blots were probed with antibodies against Lc3 & Actin as a loading control. Western blots were repeated at least three times with independent extracts. (C) Quantification of Lc3-II fold changes in WT & mutant embryos in absence or presence of Baf A1. Western blot band intensities were quantified by Lab Image. Data is combined from three independent experiments. (D) Representative confocal micrographs of GFP-Lc3 puncta present in the tail fin of optn+/+, optn delta 5n/ delta 5n, p62+/+ & p62 delta 37n/ delta 37n at 4 dpf. Scale bars, 10 μm. (E). Quantification of the number of GFP-Lc3 puncta in optn+/+, optn delta 5n/ delta 5n, p62+/+ & p62 delta 37n/ delta 37n larvae with & without Baf A1 treatment. Each larva was imaged at a pre-defined region of the tail fin (as indicated by the red boxed area in Fig3 A) (≥11 larvae/group). Results are accumulated from two independent experiments. ns, non-significant, *p10 larvae/sample). The blots were probed with antibodies against Lc3 & Actin as a loading control & Lc3-II/Lc3-I ratios are indicated below. Western blots were repeated twice with independent extracts. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30818338), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2331_rabbit-polyclonal-lc3a-antibody-310202415541914.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - UBC9 is degraded by autophagy in epithelial cells.(A) Immunolocalization of UBC9 in ultrathin sections of HKs transduced with empty or HPV16 E6/E7 vectors. Original view (left) & higher magnification (right) of boxed regions. Gold particles are selectively enriched in autophagic structures highlighted by arrows. Scale bar = 1 μm. (B) Top: Representative WB of HaCaT cells treated with the indicated autophagic activators (left) & inhibitors (right). Activation of autophagy was monitored by the conversion of LC3 (LC3-I) to the lipidated LC3 (LC3-II) form, a marker of autophagosome production induced by autophagic stimuli [41]. LC3-II accumulation was used to verify autophagic impairment [41]. Bottom: normalized UBC9 expression. Data are expressed as fold over untreated cells. Bars represent means ± SEM of n = 4 different biological replicates. ns: not significant (Kruskal–Wallis one-way ANOVA with Dunn’s post hoc test) compared to vehicle control groups. (C) Representative WB analysis of U-2 OS or MCF7 cells treated with chloroquine. n = 3 different biological replicates. (D) Representative WB analysis of MCF7 cells transduced with scramble or ATG5 shRNA. The observed ATG5 band represents the ATG5-ATG12 conjugated form. LC3-I accumulation is reported to evidence autophagic deficiencies promoted by shATG5. n = 3 replicates of a single transduction. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006262), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2331_rabbit-polyclonal-lc3a-antibody-310202415525247.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - Dram1 is required for GFP-Lc3 targeting to Mm clusters.a, b Representative confocal micrographs & quantification of GFP-Lc3 puncta in dram1∆19n/∆19n & dram1+/+ larvae in an unstimulated situation (basal autophagy, a) & following BafA1 treatment b. Each larva was imaged at a pre-defined region of the tail fin (≥11 larvae/group). Results are accumulated from two independent experiments & represented by scatter & boxplots as detailed in the “Methods” section. ns non-significant, *p 10 larvae/sample). Lc3 c & e, or p62 & Optineurin d protein levels were detected in absence or presence of BafA1, c & d, or in the presence or absence of Mm e. Actin was used as a loading control. Western Blots were repeated three, c & d, or two e times with protein extracts derived from independent experiments. The Lc3II/Actin or p62/Actin & Optineurin/Actin ratio, normalized to the control sample, is indicated below the blots. f–g Representative confocal micrographs & quantification of GFP-Lc3 co-localization with Mm clusters in infected dram1∆19n/∆19n & dram1+/+ larvae. The top images f show the entire region of imaging, while the bottom images f′ & f″ show details of GFP-Lc3 colocalization of Mm clusters in dram1∆19n/∆19n & dram1+/+ larvae. The arrowheads indicate GFP-Lc3-positive Mm clusters. The data is accumulated from two independent experiments (≥15 larvae/group) & represented by scatter & boxplots as detailed in the “Methods” section. Scale bars, 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32332700), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2331_rabbit-polyclonal-lc3a-antibody-310202415541920.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - Knockdown of FUT1 is associated with an increase in autophagic flux. (a) Immunoblot analysis of LC3-II & p62 levels in control & FUT1 knockdown cells. Total cell lysates from MCF-7 & T47D cells transfected with control or FUT1 siRNAs were collected at 120 & 96 h post-transfection, respectively. Equal amounts of cell lysates were then loaded in each lane & separated by SDS-PAGE. Immunoblot analysis was performed with LC3 & p62 antibodies. Actin was used as a loading control. The intensity of LC3-II & p62 protein bands on immunoblot were quantified & normalized to actin, & the relative levels of protein expression were expressed as fold change by setting the control group value to 1. Values shown are mean±S.E.M. of three independent experiments (***P100 cells per group (*P<0.05) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27560716), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2331_rabbit-polyclonal-lc3a-antibody-31020241553512.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - Effect of MIR376A overexpression on autophagy.(A) MCF-7 cells were co-transfected with either MIR-CNT (control plasmid) or MIR376A & GFP-LC3 plasmid, & GFP-LC3 dot formation was analyzed. White arrows indicate clusters of the GFP-LC3 dots in cells. (B) Quantification of the experiments in A. MIR376A overexpression, but not MIR-CNT expression, blocked starvation (STV)-induced autophagy (mean ± S.D. of independent experiments, n = 4, ***p<0,01). NON STV, non-starved (C) Overexpression of MIR376A resulted in a decrease in the autophagic activity of MCF-7 cells. Starvation-induced conversion of LC3-I to LC3-II in MCF-7 cells was analyzed. Tests were performed in the presence or absence of E64d (10 µg/ml) & Pepstatin A (10 µg/ml) (E+P). LC3-II/LC3-I densitometric ratios were marked. ACTB was used as a loading control. (D) MIR376A blocked starvation induced SQSTM1 degradation in MCF-7 cells. ACTB was used as a loading control. SQSTM1/ACTIN densitometric ratios were marked. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24358205), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2331_rabbit-polyclonal-lc3a-antibody-310202415535132.jpg)
![Western Blot: LC3A Antibody - BSA Free [NB100-2331] - Tau clearance in vivo & autophagy function. Clearance kinetics of photoconverted Dendra-tau measured in neurons of WT-tau & AT152T-tau fish. Measurement of intensity of red Dendra-tau signal over time reflects the clearance or degradation of tau protein. (C–F) WBs for LC3-II, a well-characterized marker of autophagosome number, demonstrate that there no differences in levels of this protein between WT-tau & A152T-tau fish either at 24 hpf (pre-phenotype; C & D) or 72 hpf (post-phenotype; E & F). (E & F) Measurements of LC3-II levels in presence or absence of ammonium chloride provides a method for measuring autophagic flux. No differences observed between the two transgenic lines at 3 dpf, suggesting that autophagy functions normally in both WT-tau & A152T-tau fish (graph represents mean ± SD of four independent clutches per group for E & F & 3for C & D; two-tailed t-test). Image collected & cropped by CiteAb from the following publication (//academic.oup.com/brain/article/140/4/1128/2980948), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2331_rabbit-polyclonal-lc3a-antibody-31020241682110.jpg)
![Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Subcellular localization of BEST1 and surface Ca2+-dependent Cl- current in patient-derived iPSC-RPEs. Western blots show similar BEST1 expression levels in WT and patient-derived iPSC-RPEs. Each sample was from one cell lysis (BEST1 and beta-actin, RPE65 and CRALBP were on two gels, respectively). Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29914), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Western-Blot-NB100-355-img0013.jpg "Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Subcellular localization of BEST1 and surface Ca2+-dependent Cl- current in patient-derived iPSC-RPEs. Western blots show similar BEST1 expression levels in WT and patient-derived iPSC-RPEs. Each sample was from one cell lysis (BEST1 and beta-actin, RPE65 and CRALBP were on two gels, respectively). Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29914), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Expression of eye-specific markers in the induced eye-like structures induced from lignin-added ES cells. (a) Higher-magnification image of the RPE like structure induced from ESCs after 12-day culture. (b) Immunostaining of eye- like structures. Eye- like structures induced from ESCs after 12-day culture were stained with antibodies against RPE65 (red) and nuclei were stained with DAPI solution (blue). Scale bar: a = 50 um, b,d = 200 um, c,e = 100 um. PLoS One. 2013 Jun 21;8(6):e66376. doi: 10.1371/journal.pone.0066376.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-355-img0014.jpg)
![Immunohistochemistry-Paraffin: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Analysis of FFPE human glioblastoma tissue section using 1:500 dilution of RPE65 [401.8B11.3D9] antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems).](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunohistochemistry-Paraffin-NB100-355-img0012.jpg)
![Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - WB analysis of RPE65 in 20ug lysate of COS7 cells expressing recombinant Human RPE65 (Lane 1) and 5ug of Bovine retinal pigment epithelium membrane fraction (Lane 2). Blot processed for detection with alkaline phosphatase conjugated goat-anti Mouse IgG secondary antibody and NBT/BCIP substrate.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Western-Blot-NB100-355-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - ICC-IF analysis of cultured ARPE19 cells, a spontaneously arising human retinal pigment epithelia cell line - 10 minutes fixation in 4% PFA, 10 minutes permeabilization in PBS containing 0.2% Triton X-100 (PBS-T), 1 hour blocking in 10% normal goat serum containing 1% BSA in PBS-T, 1:100 primary antibody dilution in PBS, ON 4C incubation.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-355-img0006.jpg)
![Immunohistochemistry-Frozen: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Staining of RPE65 in a cryosection of mouse retina tissue using RPE65 antibody (clone 401.8B11.3D9).](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunohistochemistry-Frozen-NB100-355-img0007.jpg)
![Immunohistochemistry: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Zebrafish brain ventricular area labeled with mouse anti-RPE65 (1:100). This image was submitted through a verified customer review.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunohistochemistry-NB100-355-img0011.jpg)
![Simple Western: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - iPSC-RPE from all donors express RPE marker proteins. iPSC-RPE from the patient, the patients mom, the patients dad, and the three unrelated, unaffected controls all expressed RPE65. The negative control (iPSCs) had no detectable RPE65 protein expression. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29540715/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Simple-Western-NB100-355-img0016.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Immunoblotting showing the expression of RPE-specific proteins BEST1 (NB300-164), RPE65 (NB100-355), CRALBP, and the loading control beta-Actin in iPSC-RPE cells. Two gels/blots in the same panel were prepared from the same cell lysate of each PSC-RPE to detect BEST1 + beta-Actin, and RPE65 + CRALBP, respectively. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34061021/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Knockout-Validated-NB100-355-img0015.jpg)
![Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Expression of RPE-specific marker proteins in hPSC-RPE & iPSC-RPE cells.(a–b) Immunoblotting showing the expression of RPE-specific proteins BEST1, RPE65, CRALBP, & the loading control beta -Actin in hPSC-RPE (a) & iPSC-RPE (b) cells. Two gels/blots in the same panel were prepared from the same cell lysate of each PSC-RPE to detect BEST1 + beta -Actin, & RPE65 + CRALBP, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34061021), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-355_mouse-monoclonal-rpe65-antibody-401-8b11-3d9-31020241539592.jpg)
![Immunocytochemistry/ Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - BMP5 induces ectopic RPE development in the central NR at optic cup stages. (A,B) Peripheral, untreated chick eye at E8 showing pigmentation & MITF expression being restricted to the outer layer of the eye. The arrowheads indicate the peripheral NR. (C-F) Higher magnification of the central chick eye at E8 showing the pigmented RPE, where RPE65 protein is detected (arrows). Faint Wnt2b & strong Vsx2 expression is detected in the central NR. The arrows indicate the RPE. (G,H) Following BMP5 application at E3.5/4, the NR detached (arrowhead) & MITF protein is now detected in the central NR (cNR). Note that a part of the cNR has RPE-like morphology (eRPE). (I-L) Higher magnification images of the eRPE. Ectopic pigment granulae, RPE65 protein & strong Wnt2b expression are detected in this region, whereas Vsx2 expression is downregulated (arrowheads). (M-O) Untreated chick eye at E8 showing pigmentation & MITF (arrow) & VSX2 protein distribution, restricted to the RPE & NR, respectively. (P-R) Following BMP5 application at E3.5/4, ectopic pigmentation & nuclear MITF protein are detected in the inner optic cup (arrowheads), whereas VSX2 protein is only weakly or not detected. The arrows indicate the RPE. (S) Graphical representation of the average thickness of the inner layer of the untreated (control) & BMP5-treated eye at E8. All expression pattern studies included n≥5. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28546339), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-355_mouse-monoclonal-rpe65-antibody-401-8b11-3d9-310202415541976.jpg)
![Immunocytochemistry/ Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - BMP5 induces ectopic RPE development in the central NR at optic cup stages. (A,B) Peripheral, untreated chick eye at E8 showing pigmentation & MITF expression being restricted to the outer layer of the eye. The arrowheads indicate the peripheral NR. (C-F) Higher magnification of the central chick eye at E8 showing the pigmented RPE, where RPE65 protein is detected (arrows). Faint Wnt2b & strong Vsx2 expression is detected in the central NR. The arrows indicate the RPE. (G,H) Following BMP5 application at E3.5/4, the NR detached (arrowhead) & MITF protein is now detected in the central NR (cNR). Note that a part of the cNR has RPE-like morphology (eRPE). (I-L) Higher magnification images of the eRPE. Ectopic pigment granulae, RPE65 protein & strong Wnt2b expression are detected in this region, whereas Vsx2 expression is downregulated (arrowheads). (M-O) Untreated chick eye at E8 showing pigmentation & MITF (arrow) & VSX2 protein distribution, restricted to the RPE & NR, respectively. (P-R) Following BMP5 application at E3.5/4, ectopic pigmentation & nuclear MITF protein are detected in the inner optic cup (arrowheads), whereas VSX2 protein is only weakly or not detected. The arrows indicate the RPE. (S) Graphical representation of the average thickness of the inner layer of the untreated (control) & BMP5-treated eye at E8. All expression pattern studies included n≥5. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28546339), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-355_mouse-monoclonal-rpe65-antibody-401-8b11-3d9-31020241682152.jpg)
![Immunocytochemistry/ Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - BMP5 induces ectopic RPE development in the central NR at optic cup stages. (A,B) Peripheral, untreated chick eye at E8 showing pigmentation & MITF expression being restricted to the outer layer of the eye. The arrowheads indicate the peripheral NR. (C-F) Higher magnification of the central chick eye at E8 showing the pigmented RPE, where RPE65 protein is detected (arrows). Faint Wnt2b & strong Vsx2 expression is detected in the central NR. The arrows indicate the RPE. (G,H) Following BMP5 application at E3.5/4, the NR detached (arrowhead) & MITF protein is now detected in the central NR (cNR). Note that a part of the cNR has RPE-like morphology (eRPE). (I-L) Higher magnification images of the eRPE. Ectopic pigment granulae, RPE65 protein & strong Wnt2b expression are detected in this region, whereas Vsx2 expression is downregulated (arrowheads). (M-O) Untreated chick eye at E8 showing pigmentation & MITF (arrow) & VSX2 protein distribution, restricted to the RPE & NR, respectively. (P-R) Following BMP5 application at E3.5/4, ectopic pigmentation & nuclear MITF protein are detected in the inner optic cup (arrowheads), whereas VSX2 protein is only weakly or not detected. The arrows indicate the RPE. (S) Graphical representation of the average thickness of the inner layer of the untreated (control) & BMP5-treated eye at E8. All expression pattern studies included n≥5. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28546339), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-355_mouse-monoclonal-rpe65-antibody-401-8b11-3d9-31020241682148.jpg)
![Dual RNAscope ISH-IHC: xCT Antibody [NB300-318] - Formalin-fixed paraffin-embedded tissue sections of human stomach were probed for xCT mRNA (ACD RNAScope Probe, catalog #422688; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Rabbit Polyclonal (Novus Biologicals catalog # NB300-318) at 0.25ug/mL with 1 hour incubation at room temperature followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody (Catalog # VC003) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to glandular cells.](http://images.novusbio.com/fullsize/xCT-Antibody-Dual-RNAscope-ISH-IHC-NB300-318-img0012.jpg "<b>Orthogonal Strategies Validation. </b>Dual RNAscope ISH-IHC: xCT Antibody [NB300-318] - Formalin-fixed paraffin-embedded tissue sections of human stomach were probed for xCT mRNA (ACD RNAScope Probe, catalog #422688; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Rabbit Polyclonal (Novus Biologicals catalog # NB300-318) at 0.25ug/mL with 1 hour incubation at room temperature followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody (Catalog # VC003) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to glandular cells.")
![<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Simple Western: xCT Antibody [NB300-318] - Simple Western lane view shows a specific band for xCT using NB300-318 at 25 ug/ml in HeLa and HeLa + DEM cell lysates. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/xCT-Antibody-Simple-Western-NB300-318-img0013.jpg)
![Western Blot: xCT Antibody [NB300-318] - Western blot analysis of protein isolated from subcutaneous tumors derived from in vivo growth of the clones relative to WT-derived tumors revealed that xCT levels remained low, phospho-STAT5 (p-STAT5) levels remained high, and phospho-STAT3 (p-STAT3) levels remained unchanged in the absence of SH-4-54. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0161202), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/xCT-Antibody-Western-Blot-NB300-318-img0015.jpg)
![Immunohistochemistry: xCT Antibody [NB300-318] - xCT staining in the absorptive epithelia of small intestinal villi detected using NB300-318.](http://images.novusbio.com/fullsize/xCT-Antibody-Immunohistochemistry-NB300-318-img0006.jpg)
![Flow Cytometry: xCT Antibody [NB300-318] - An intracellular stain was performed on HeLa cells with NB300-318AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-318-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: xCT Antibody [NB300-318] - xCT antibody was tested in HepG2 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/xCT-Antibody-Immunocytochemistry-Immunofluorescence-NB300-318-img0005.jpg)
![Flow Cytometry: xCT Antibody [NB300-318] - An intracellular stain was performed on HeLa cells with xCT Antibody NB300-318AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-318-img0010.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: xCT Antibody [NB300-318] - Total protein from Human HeLa cells treated with and without 0.1 mM Diethyl Maleate for 24 hours was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the increase in xCT expression with treatment.](http://images.novusbio.com/fullsize/xCT-Antibody-Western-Blot-NB300-318-img0007.jpg)
![Flow Cytometry: xCT Antibody [NB300-318] - An intracellular stain was performed on HeLa with xCT Antibody NB300-318 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG APC-conjugated Secondary Antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-318-img0008.jpg)
![Simple Western: xCT Antibody [NB300-318] - Simple Western lane view shows a specific band for xCT using NB300-318 at 25 ug/mL in HepG2 cell lysates and antibody at 25 ug/mL. Electropherogram image of corresponding Simple Western lane view at WES molecular weight of 63 kDa. Image reported by internal validation.](http://images.novusbio.com/fullsize/xCT-Antibody-Simple-Western-NB300-318-img0014.jpg)
![Western Blot: xCT Antibody - BSA Free [NB300-318] - Subcutaneous injection into nude mice revealed that (A) MDA-MB-231 SH-4-54-resistant clone #2 proliferated at a slower rate than its wild-type (WT) counterpart in vivo. (B) qPCR demonstrated that xCT mRNA levels were lower in tumours isolated from animals injected with clone #2 relative to WT cells (2 animals per treatment group). (C) Western blot analysis of protein isolated from subcutaneous tumours derived from in vivo growth of the clones relative to WT-derived tumours revealed that xCT levels remained low, phospho-STAT5 (p-STAT5) levels remained high, & phospho-STAT3 (p-STAT3) levels remained unchanged in the absence of SH-4-54. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0161202), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-318_rabbit-polyclonal-xct-antibody-310202415392520.jpg)
![Western Blot: xCT Antibody - BSA Free [NB300-318] - A link between KSHV latency & the MC1-R signaling axis in skin-derived cell lines. (a) Western blot analysis of phosphorylated NF-kappa B p65, MC1-R, & TRP-1 in total cell lysates extracted from MeWo (a) or Mel1700 (b) cells either uninfected (control) or acutely infected with KSHV for 0.3 h, 1 h, 3 h, or 6 h. GAPDH was used as loading control. (c) ImageJ quantitation of the p65 band intensities in (a) & (b) relative to GAPDH controls. (d) Mel1700 cells were infected in 6-well plates with increasing volumes (mL/well) of concentrated supernatant containing infectious KSHV, & total RNA from infected cells was subjected to RT-PCR using primer sets for host anti-inflammatory MC1R, POMC, & SLC7A11. (e) Equal aliquots from the same RNA used in (d) were subjected to RT-PCR analysis for select viral latency & cell growth control genes (i.e., GPCR, LANA, & v-FLIP). (f) Western blot analysis of the melanoma cell marker, Melan A, & anti-inflammatory genes MC1-R, TRP1, & SLC7A11 in total cell lysates of uninfected (−) or chronically infected (+) long-term cultures of MeWo-KSHV & Mel1700-KSHV cells. GAPDH was used as an internal control for both the RT-PCR (e) & western blot assays. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24701351), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-318_rabbit-polyclonal-xct-antibody-31020241621818.jpg)
![Western Blot: xCT Antibody - BSA Free [NB300-318] - A link between KSHV latency & the MC1-R signaling axis in skin-derived cell lines. (a) Western blot analysis of phosphorylated NF-kappa B p65, MC1-R, & TRP-1 in total cell lysates extracted from MeWo (a) or Mel1700 (b) cells either uninfected (control) or acutely infected with KSHV for 0.3 h, 1 h, 3 h, or 6 h. GAPDH was used as loading control. (c) ImageJ quantitation of the p65 band intensities in (a) & (b) relative to GAPDH controls. (d) Mel1700 cells were infected in 6-well plates with increasing volumes (mL/well) of concentrated supernatant containing infectious KSHV, & total RNA from infected cells was subjected to RT-PCR using primer sets for host anti-inflammatory MC1R, POMC, & SLC7A11. (e) Equal aliquots from the same RNA used in (d) were subjected to RT-PCR analysis for select viral latency & cell growth control genes (i.e., GPCR, LANA, & v-FLIP). (f) Western blot analysis of the melanoma cell marker, Melan A, & anti-inflammatory genes MC1-R, TRP1, & SLC7A11 in total cell lysates of uninfected (−) or chronically infected (+) long-term cultures of MeWo-KSHV & Mel1700-KSHV cells. GAPDH was used as an internal control for both the RT-PCR (e) & western blot assays. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24701351), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-318_rabbit-polyclonal-xct-antibody-310202416212337.jpg)
![Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Western blot analysis of the normal and mutant human Best1 protein in transiently transfected MDCK cells. Best1 proteins are detectable as a 68 kDa band in all transfected cells, but not in non-transfected controls (MDCK lane). Actin bands are shown to indicate equal loading of cell lysates. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/14/7/15121), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Bestrophin-1-Antibody-E6-6-BSA-Free-Western-Blot-NB300-164-img0007.jpg "Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Western blot analysis of the normal and mutant human Best1 protein in transiently transfected MDCK cells. Best1 proteins are detectable as a 68 kDa band in all transfected cells, but not in non-transfected controls (MDCK lane). Actin bands are shown to indicate equal loading of cell lysates. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/14/7/15121), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - X-Z confocal single image scan of transiently transfected cells with different BEST1 cDNA constructs showing mislocalization of mutants Y85H, Q96R, L100R and Y227N. Cells were stained for Best1 (green), beta-catenin (red) and nuclei (blue). Scale bar = 10 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/14/7/15121), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Bestrophin-1-Antibody-E6-6-BSA-Free-Immunocytochemistry-Immunofluorescence-NB300-164-img0008.jpg)
![Immunohistochemistry-Paraffin: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Bestrophin 1 was detected in immersion fixed paraffin sections of human small intestine using t Mouse Anti-Human Bestrophin 1 Monoclonal Antibody (Catalog # NB300-164) at 5 ug/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cell surface and extracellular.](http://images.novusbio.com/fullsize/Bestrophin-1-Antibody-E6-6-BSA-Free-Immunohistochemistry-Paraffin-NB300-164-img0005.jpg)
![Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Detection of Bestrophin (68 kDa) from human RPE cell lysate.](http://images.novusbio.com/fullsize/Bestrophin-1-Antibody-E6-6-BSA-Free-Western-Blot-NB300-164-img0003.jpg)
![Immunohistochemistry-Paraffin: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Bestrophin 1 was detected in immersion fixed paraffin-embedded sections of human brain using Mouse Anti-Human Bestrophin 1 (E6-6) Monoclonal Antibody (Catalog # NB300-164) at 1:300 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm in neurons.](http://images.novusbio.com/fullsize/Bestrophin-1-Antibody-E6-6-BSA-Free-Immunohistochemistry-Paraffin-NB300-164-img0004.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Immunoblotting showing the expression of RPE-specific proteins BEST1 (NB300-164), RPE65 (NB100-355), CRALBP, and the loading control beta-Actin in iPSC-RPE cells. Two gels/blots in the same panel were prepared from the same cell lysate of each PSC-RPE to detect BEST1 + beta-Actin, and RPE65 + CRALBP, respectively. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34061021/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Bestrophin-1-Antibody-E6-6-BSA-Free-Knockout-Validated-NB300-164-img0009.jpg)
![Dual RNAscope ISH-IHC: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Formalin-fixed paraffin-embedded tissue sections of human duodenum were probed for Bestrophin 1 mRNA (ACD RNAScope Probe, catalog # 433181; Fast Red chromogen, ACD catalog # 322360). Adjacent tissue section was processed for immunohistochemistry using mouse anti-human (Novus Biologicals catalog # NB300-164) at 0.3ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). IHC signal is confined to cytoplasm.](http://images.novusbio.com/fullsize/Bestrophin-1-Antibody-E6-6-BSA-Free-Dual-RNAscope-ISH-IHC-NB300-164-img0006.jpg)
![Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - (a) Schematic drawing showing localization of the different mutations (black diamonds) tested in our study (modified from [12]); (b) Western blot analysis of the normal & mutant human Best1 protein in transiently transfected MDCK cells. Best1 proteins are detectable as a 68 kDa band in all transfected cells, but not in non-transfected controls (MDCK lane). Actin bands are shown to indicate equal loading of cell lysates. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23880862), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-31020241534336.jpg)
![Immunocytochemistry/ Immunofluorescence: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Subcellular localization of WT & mutant BEST1 in iPSC-RPEs. Confocal images showing the co-staining of BEST1, Collagen IV & Hoechst in iPSC-RPEs derived from a WT donor or patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31836750), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-310202415363746.jpg)
![Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - (a) HPRT & BEST1 mRNAs are expressed in MDCK & RPE-J cells. M–100 bp ladder, N–negative control; (b) Quantification of BEST1 expression levels between MDCK & RPE-J cells using quantitative Real-Time PCR. Fold change variation in BEST1 expression levels is reported as 2^-delta delta Ct value, the reference mRNA being HPRT (mean ± SEM., n = 2); (c) Western blot analysis—Best1 protein is not synthesized by RPE-J or MDCK cells. After transfection, MDCK produce human Best1 at 68 kDa. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23880862), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-310202415284544.jpg)
![Immunocytochemistry/ Immunofluorescence: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Characterization of WT iPSC & iPSC-RPE.(A) Phase picture of established WT iPSC line before differentiation. Scale bar, 400 μm. (B) Immunocytofluorescence images of pluripotency markers in established iPSC. Scale bar, 200 μm. (C) Confocal images showing plasma membrane localization of BEST1. Scale bar, 10 μm. (D) Comparison of current amplitudes in iPSC-RPEs from two BEST1 WT donors. Bar chart showing the steady-state current amplitudes at 0 [Ca2+]i, 1.2 μM [Ca2+]i, & 1.2 μM [Ca2+]i + 100 μM NFA in RPEs from two distinct BEST1 WT human donors; n = 5–6. ∗$p<0.05 compared to current amplitudes at 1.2 μM [Ca2+]i from donor #1 & #2, respectively, using two-tailed unpaired Student t test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29063836), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-31020241535684.jpg)
![Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - CRISPR/Cas9-mediated gene silencing in combination with augmentation.(a) Augmented BEST1-GFP & endogenous BEST1 were detected by immunoblotting in hPSC-RPE cells. (b) Schematic of the baculovirus-based silencing (BVSi) vector. (c) Immunoblotting showing the knockdown of endogenous BEST1 expression with BVSi vectors & augmentation of wobble BEST1-mCherry in WT hPSC-RPE cells. (d) Immunoblotting showing the knockdown of endogenous BEST1 expression with BVSi 3–8 & augmentation of wobble BEST1-mCherry in hPSC-RPE cells carrying BEST1 gain-of-function mutations. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34061021), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-31020241537190.jpg)
![Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - CRISPR/Cas9-mediated gene silencing in combination with augmentation.(a) Augmented BEST1-GFP & endogenous BEST1 were detected by immunoblotting in hPSC-RPE cells. (b) Schematic of the baculovirus-based silencing (BVSi) vector. (c) Immunoblotting showing the knockdown of endogenous BEST1 expression with BVSi vectors & augmentation of wobble BEST1-mCherry in WT hPSC-RPE cells. (d) Immunoblotting showing the knockdown of endogenous BEST1 expression with BVSi 3–8 & augmentation of wobble BEST1-mCherry in hPSC-RPE cells carrying BEST1 gain-of-function mutations. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34061021), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-31020241539730.jpg)
![Western Blot: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Expression of RPE-specific marker proteins in hPSC-RPE & iPSC-RPE cells.(a–b) Immunoblotting showing the expression of RPE-specific proteins BEST1, RPE65, CRALBP, & the loading control beta -Actin in hPSC-RPE (a) & iPSC-RPE (b) cells. Two gels/blots in the same panel were prepared from the same cell lysate of each PSC-RPE to detect BEST1 + beta -Actin, & RPE65 + CRALBP, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34061021), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-31020241535628.jpg)
![Immunocytochemistry/ Immunofluorescence: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Impact of BEST1 pathogenic variants in bestrophin-1 RPE localization. Cryosections obtained from the BD donors & an 88-year-old control were labeled with antibodies specific to bestrophin-1 (green), while cell nuclei have been labeled with TO-PRO-3 (blue). Bruch’s membrane is indicated by the hashed white line. Arrow = mislocalized apical RPE distribution of bestrophin-1; arrowheads = basolateral RPE distribution of bestrophin-1; double arrowheads = intracellular bestrophin-1. Scale bar = 40 μm (all images). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33154968), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-310202415395959.jpg)
![Immunocytochemistry/ Immunofluorescence: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - Subcellular localization of WT & mutant BEST1 in iPSC-RPEs. Confocal images showing the co-staining of BEST1, Collagen IV & Hoechst in iPSC-RPEs derived from a WT donor or patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31836750), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-310202415175245.jpg)
![Immunocytochemistry/ Immunofluorescence: Bestrophin 1 Antibody (E6-6) - BSA Free [NB300-164] - (a) X-Z confocal single image scan of transiently transfected cells with different BEST1 cDNA constructs showing mislocalization of mutants Y85H, Q96R, L100R & Y227N. Cells were stained for Best1 (green), beta -catenin (red) & nuclei (blue). Scale bar = 10 μm; (b) Z-series confocal stack signals corresponding to each labeling were quantified. Curves indicate the pixel intensity of each section along the Z-axis for each cell (Best1, green; beta -catenin, red; nuclei, blue). The black vertical line indicates the Z-focal plane chosen as threshold for apical & basolateral domains separation. Basolateral & apical sides are as indicated. Horizontal axis represents μm distance & vertical axis shows pixel intensities; (c) Bar graph illustrating quantification of Best1 mutants distribution in the basolateral & apical domains of the cells compared with normal protein (mean ± SEM., n = 10, *p < 0.01, ***p < 0.0001). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23880862), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-164_mouse-monoclonal-bestrophin-1-antibody-e6-6-31020241621835.jpg)
![Immunocytochemistry/Immunofluorescence: SLC31A1/CTR1 Antibody [NB100-402] - CTR1 antibody was tested in NIH-3T3 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-402-img0004.jpg "Immunocytochemistry/Immunofluorescence: SLC31A1/CTR1 Antibody [NB100-402] - CTR1 antibody was tested in NIH-3T3 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).")
![Immunohistochemistry: SLC31A1/CTR1 Antibody [NB100-402] - Panel 1: human CTR1 staining of breast cancer tissue. Panel 2: human CTR1-antigen competition in breast cancer tissue.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-Immunohistochemistry-NB100-402-img0002.jpg)
![Immunohistochemistry: SLC31A1/CTR1 Antibody [NB100-402] - Left panel: Antibody staining of hCTR1 overexpressing cell line. Right panel: Antibody plus peptide competition staining.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-Immunohistochemistry-NB100-402-img0003.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.](http://images.novusbio.com/fullsize/LC3A-Antibody-Western-Blot-NBP1-19167-img0012.jpg "<b>Biological Strategies Validation. </b>Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: LC3A Antibody [NBP1-19167] - LC3/MAP1 [NBP1-19167] - LC3 antibody was tested in HeLa cells with Dylight 488 (green). Cells were treated overnight with 50 uM chloroquine to induce autophagosome formation. Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-19167-img0013.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse brain using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the cells with highest positivity in various neurons.](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0014.jpg)
![Western Blot: LC3/MAP1LC3A Antibody [NBP1-19167] - Human brain lysate.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Western-Blot-NBP1-19167-img0004.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse liver using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the hepatocytes and other liver cells.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0010.jpg)
![Simple Western: LC3A Antibody [NBP1-19167] - Image shows a specific band for LC3 in 0.5 mg/mL of Neuro2A lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Simple-Western-NBP1-19167-img0009.jpg)
![Western Blot: DIO3 Antibody [NBP1-05767] - Detection of Dio3 in rat placenta.](http://images.novusbio.com/fullsize/DIO3-Antibody-Western-Blot-NBP1-05767-img0002.jpg "Western Blot: DIO3 Antibody [NBP1-05767] - Detection of Dio3 in rat placenta.")
![Flow Cytometry: DIO3 Antibody [NBP1-05767] - Analysis using the Biotin conjugate of NBP1-05767. Dio3 staining of mouse hepatic stellate cell cultured for 7 days. Image from verified customer review.](http://images.novusbio.com/fullsize/DIO3-Antibody-Flow-Cytometry-NBP1-05767-img0005.jpg)
![Western Blot: DIO3 Antibody [NBP1-05767] - Detection of Dio3 in rabbit brain whole cell homogenate. Photo courtesy of product review by verified customer.](http://images.novusbio.com/fullsize/DIO3-Antibody-Western-Blot-NBP1-05767-img0003.jpg)
![Western Blot: xCT Antibody [NB300-317] - Total protein from human HeLa, Huvec, HCT-116 and A549 cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/xCT-Antibody-Western-Blot-NB300-317-img0011.jpg "Western Blot: xCT Antibody [NB300-317] - Total protein from human HeLa, Huvec, HCT-116 and A549 cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: xCT Antibody [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped and form clusters in MS patients, whereas in controls, CD68+ cells appear isolated and long shaped. Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/xCT-Antibody-Immunohistochemistry-Paraffin-NB300-317-img0015.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: xCT Antibody [NB300-317] - Total protein from Human HeLa cells treated with and without 0.1 mM Diethyl Maleate for 24 hours was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the increase in xCT expression with treatment.](http://images.novusbio.com/fullsize/xCT-Antibody-Western-Blot-NB300-317-img0012.jpg)
![Flow Cytometry: xCT Antibody [NB300-317] - An intracellular stain was performed on HeLa cells with NB300-317G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-317-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: xCT Antibody [NB300-317] - xCT antibody was tested in HepG2 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/xCT-Antibody-Immunocytochemistry-Immunofluorescence-NB300-317-img0005.jpg)
![Flow Cytometry: xCT Antibody [NB300-317] - An intracellular stain was performed on HeLa with NB300-317 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG APC-conjugated Secondary Antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-317-img0013.jpg)
![Simple Western: xCT Antibody [NB300-317] - (1) ladder, (2) no lysate + xCT, 100ug/ml, (3) human brain frontal cortex membrane lysate,no primary antibody, (4-7) human brain lysates, 0.03mg/ml, xCT, 100ug/ml.](http://images.novusbio.com/fullsize/xCT-Antibody-Simple-Western-NB300-317-img0010.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. A. Triple immunofluorescence staining for xCT (green), CD68 (red) & Hoechst 33258 (blue) in spinal cord of control (left) & MS patients (right). A high expression of xCT was detected in CD68+ infiltrating macrophages (arrows) associated with blood vessels, which are virtually absent in controls. Note that overall xCT expression is enhanced in MS tissue. B. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped & form clusters in MS patients, whereas in controls, CD68+ cells appear isolated & long shaped. Scale bar = 50 μm. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202415284530.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. A. Triple immunofluorescence staining for xCT (green), CD68 (red) & Hoechst 33258 (blue) in spinal cord of control (left) & MS patients (right). A high expression of xCT was detected in CD68+ infiltrating macrophages (arrows) associated with blood vessels, which are virtually absent in controls. Note that overall xCT expression is enhanced in MS tissue. B. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped & form clusters in MS patients, whereas in controls, CD68+ cells appear isolated & long shaped. Scale bar = 50 μm. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202415392541.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is increased in the CNS of rats with EAE. A. Histogram showing the neurological score during the course of acute EAE induced in Lewis rats by immunization with myelin basic protein. The peak of neurological disability was at day 14 post-immunization, which was selected for obtaining tissue samples. B. xCT mRNA (left) & protein (right) expression in spinal cord from control & acute EAE rats, as assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5-6). C. Double immunofluorescence for xCT (green) & OX-42 (red), a marker of microglia & infiltrating macrophages. OX42+ cells express high xCT levels in acute EAE. Both meninges (asterisk in top) & infiltrating cells (bottom) in inflammatory foci show high levels of xCT in rat spinal cord with EAE as compared to controls. D. Microglial cells (OX42+ cells) of EAE rats have higher xCT levels in spinal cord than controls. Notice the difference between resting microglia in control rats, with ramified morphology (arrows in control) & microglia in EAE showing round shaped morphology, characteristic of its activated state (arrows in EAE). Scale bar = 20 μm.E. xCT mRNA (left) & protein (right) expression in spinal cord from control & chronic EAE mice, assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5). Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202416205190.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is increased in the CNS of rats with EAE. A. Histogram showing the neurological score during the course of acute EAE induced in Lewis rats by immunization with myelin basic protein. The peak of neurological disability was at day 14 post-immunization, which was selected for obtaining tissue samples. B. xCT mRNA (left) & protein (right) expression in spinal cord from control & acute EAE rats, as assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5-6). C. Double immunofluorescence for xCT (green) & OX-42 (red), a marker of microglia & infiltrating macrophages. OX42+ cells express high xCT levels in acute EAE. Both meninges (asterisk in top) & infiltrating cells (bottom) in inflammatory foci show high levels of xCT in rat spinal cord with EAE as compared to controls. D. Microglial cells (OX42+ cells) of EAE rats have higher xCT levels in spinal cord than controls. Notice the difference between resting microglia in control rats, with ramified morphology (arrows in control) & microglia in EAE showing round shaped morphology, characteristic of its activated state (arrows in EAE). Scale bar = 20 μm.E. xCT mRNA (left) & protein (right) expression in spinal cord from control & chronic EAE mice, assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5). Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202416205138.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Analysis in human cerebral cortex and liver tissues. Corresponding Myosin 5a RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0011.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Analysis in human cerebral cortex and liver tissues. Corresponding Myosin 5a RNA-seq data are presented for the same tissues.")
![<b>Orthogonal Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Myosin 5a Antibody [NBP1-92156] - Staining of human cell line A-431 shows localization to microtubule organizing center & focal adhesion sites. Antibody staining shown in green.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-92156-img0005.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Staining of human kIdney shows moderate memberanous positivity in cells in tubules.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0013.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Staining of human cerebellum shows strong cytoplasmic positivity in Purkinje cells.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0002.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Staining of human cerebral cortex shows strong membranous positivity in neuropil.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0006.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Staining of human hippocampus shows strong cytoplasmic positivity in pyramidal cells.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0009.jpg)
![Immunohistochemistry: POMC Antibody [NB100-1533] - Representative confocal images of POMC in POMC-transfected WT and Sel1L-/- N2a cells. White arrows point to POMC-containing secretory granules, while yellow arrows point to perinuclear POMC. KDEL marks the ER. Representative data from at least 2 independent experiments are shown. Image collected and cropped by CiteAb from the following publication (jci.org/articles/view/96420), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/POMC-Antibody-Immunohistochemistry-NB100-1533-img0008.jpg "Immunohistochemistry: POMC Antibody [NB100-1533] - Representative confocal images of POMC in POMC-transfected WT and Sel1L-/- N2a cells. White arrows point to POMC-containing secretory granules, while yellow arrows point to perinuclear POMC. KDEL marks the ER. Representative data from at least 2 independent experiments are shown. Image collected and cropped by CiteAb from the following publication (jci.org/articles/view/96420), licensed under a CC-BY license.")
![Flow Cytometry: POMC Antibody [NB100-1533] - Flow cytometric analysis of paraformaldehyde fixed A431 cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/POMC-Antibody-Flow-Cytometry-NB100-1533-img0006.jpg)
![Immunohistochemistry-Paraffin: POMC Antibody [NB100-1533] - Staining of paraffin embedded Human Pituitary Gland. Antibody at 2 ug/mL. Steamed antigen retrieval with Tris/EDTA buffer pH 9, HRP-staining.](http://images.novusbio.com/fullsize/POMC-Antibody-Immunohistochemistry-Paraffin-NB100-1533-img0003.jpg)
![Immunohistochemistry: POMC Antibody [NB100-1533] - Representative immunofluorescence images of (B) POMC as a prohormone (n = 5-6 each) in the ARC of mice approximately 5 to 10 weeks of age. Image collected and cropped by CiteAb from the following publication (jci.org/articles/view/96420), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/POMC-Antibody-Immunohistochemistry-NB100-1533-img0007.jpg)
![Immunocytochemistry/ Immunofluorescence: POMC Antibody [NB100-1533] - Pathogenic POMC-C28F mutation is completely rescued by an intragenic suppressor mutation C50S.(A) Schematic diagram showing the sequence & positions of Cys residues in POMC-WT, C28F, & C28F/C50S. (B) Western blot analyses of POMC-Flag immunoprecipitates in HEK293T cells transfected with a combination of Myc- or Flag-tagged POMC under nonreducing (– beta -ME) & reducing (+ beta -ME) SDS-PAGE. Two panels were from the same experiment at the same exposure time, with the irrelevant lanes in the middle cut off. (C) Sucrose gradient fractionation & Western blot analysis of HEK293T cells expressing POMC-C28F or -C28F/C50S under nonreducing (– beta -ME) & reducing (+ beta -ME) SDS-PAGE. (D) Metabolic labeling experiments to visualize the maturation of nascent POMC in HEK293T cells transfected with POMC-Myc. Cells were pulsed for 30 minutes & chased for the indicated times, followed by immunoprecipitation with anti-Myc agarose beads & separation on SDS-PAGE gels under nonreducing or reducing conditions & autoradiography. (E) Representative confocal images of POMC in POMC-transfected WT N2a cells. White arrows point to secreted POMC in granules, while yellow arrows point to perinuclear POMC, possibly in the form of aggregates. KDEL marks the ER. Representative data from at least 2 independent experiments shown. Image collected & cropped by CiteAb from the following publication (//www.jci.org/articles/view/96420), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1533_goat-polyclonal-pomc-antibody-310202415535174.jpg)
![Western Blot: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - Analysis of SLC31A1/CTR1 in MCF7 and HeLa at 2 ug/ml.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-5E6-1B4-BSA-Free-Western-Blot-NBP2-36573-img0001.jpg "Western Blot: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - Analysis of SLC31A1/CTR1 in MCF7 and HeLa at 2 ug/ml.")
![Immunocytochemistry/Immunofluorescence: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti SLC31A1/CTR1 (5E6.1B4) NBP2-36573 at a 1:50 dilution overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-5E6-1B4-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-36573-img0009.jpg)
![Immunohistochemistry: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - IL-17 induces cellular copper uptake through induction of STEAP4. Western blots analysis for copper trafficking-associated proteins from lysates of mouse colon epithelial organoids treated with different inflammatory cytokines for 8h. Three independent experiments were done and representative blots were shown. Untr untreated. IL-17 primed or unprimed mouse colon organoids were stained for STEAP4 (St4), E-cadherin (E-cad) and SLC31A1/CTR1 and integrin alpha. Scale bar, 100 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-020-14698-y), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-5E6-1B4-BSA-Free-Immunohistochemistry-NBP2-36573-img0010.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - STEAP4 promotes colitis-associated colon tumorigenesis. Western blot analysis of colon tissue lysates from mice treated with DSS water for indicated days. Western blot analysis of colon tissue lysates from mice treated with DSS water for indicated days. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32060280/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-5E6-1B4-BSA-Free-Western-Blot-NBP2-36573-img0011.jpg)
![Immunohistochemistry-Paraffin: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - Analysis of a formalin fixed and paraffin embedded tissue section of human urinary bladder transitional cell carcinoma (NBP2-30234) using purified CTR1/SLC31A1 antibody clone 5E6.1B4 at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-5E6-1B4-BSA-Free-Immunohistochemistry-Paraffin-NBP2-36573-img0002.jpg)
![Immunohistochemistry-Paraffin: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - Analysis of a FFPE tissue section of normal breast tissue from a human breast cancer patient (NBP2-30234) using purified CTR1/SLC31A1 antibody clone 5E6.1B4 at 5 ug/ml concentration. The antibody generated a very strong cytoplasmic staining in the myo-epithelial cells in the tested section.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-5E6-1B4-BSA-Free-Immunohistochemistry-Paraffin-NBP2-36573-img0008.jpg)
![Immunohistochemistry-Paraffin: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - Analysis of a FFPE tissue section of normal skin from a human breast cancer patient (NBP2-30234) using purified CTR1/SLC31A1 antibody clone 5E6.1B4 at 5 ug/ml concentration. The antibody developed a strong cytoplasmic staining in the outer layer of stratum spinosum and the cells of stratum granulosum/ granular layer of skin epidermis. The endothelial cells in the dermis of the section also showed positivity for SLC31A1/CTR1.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-5E6-1B4-BSA-Free-Immunohistochemistry-Paraffin-NBP2-36573-img0006.jpg)
![Immunohistochemistry-Paraffin: SLC31A1/CTR1 Antibody (5E6.1B4) - BSA Free [NBP2-36573] - Aanalysis of a FFPE tissue section of human small bowel malignant stromal tumor (NBP2-30234) using purified CTR1/SLC31A1 antibody clone 5E6.1B4 at 5 ug/ml concentration. The cancer cells developed moderate to strong positivity for CTR1/SLC31A1 protein.](http://images.novusbio.com/fullsize/SLC31A1-CTR1-Antibody-5E6-1B4-BSA-Free-Immunohistochemistry-Paraffin-NBP2-36573-img0007.jpg)